Phaseline

Targets › DENV1

DENV1: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 4; Infectious disease, Immunology; next expected readout Dec 2027.

Open in Phaseline: the race on DENV1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Sao Paulo General HospitalDengue 1,2,3,4 (attenuated) vaccine
Live attenuated tetravalent dengue vaccine (DENV-1, DENV-3, DENV-4, and chimeric DENV-2)
DENV1, DENV2, DENV3, DENV4Phase 4Rheumatoid Arthritis (RA)Dec 2027
Beth KirkpatrickTV005
Live attenuated tetravalent dengue vaccine (rDEN1Δ30, rDEN2/4Δ30(ME), rDEN3Δ30/31, rDEN4Δ3
DENV1, DENV2, DENV3, DENV4Phase 2Dengue–

Conditions

Dengue (1) Rheumatoid Arthritis (RA) (1)

Modalities

mixed (1), other (1)

Companies

Beth Kirkpatrick (1) University of Sao Paulo General Hospital (1)

Related targets

DENV2 (2) DENV3 (2) DENV4 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.